What is myelin oligodendrocyte glycoprotein (MOG)-associated disease (MOGAD)?

MOG-Associated Disease (MOGAD)

MOG-associated disease (MOGAD) is a distinct autoimmune inflammatory demyelinating disorder of the central nervous system, characterized by antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG), and is now recognized as a separate disease entity from both multiple sclerosis (MS) and aquaporin-4 (AQP4)-positive neuromyelitis optica spectrum disorder (NMOSD). 1

Core Disease Characteristics

MOGAD represents a unique immunopathogenic process with several defining features:

• Antibody-mediated pathology: The disease is driven by IgG antibodies targeting full-length, conformationally intact MOG protein on the outer surface of myelin sheaths 1
• Distinct immunopathology: Neuropathological studies demonstrate discrete histopathological features including primary demyelination with intralesional complement and IgG deposits 1
• Serological distinction: Almost all MOG-IgG-positive patients lack AQP4-IgG antibodies, confirming these are separate disease processes 1

Clinical Presentations

The clinical spectrum of MOGAD is heterogeneous but follows recognizable patterns:

Primary Manifestations

• Optic neuritis (ON): Often bilateral, severe, with prominent papilledema/papillitis and longitudinally extensive optic nerve lesions (>1/2 length of pre-chiasmal nerve) 1, 2
• Myelitis: Frequently presents as longitudinally extensive transverse myelitis (LETM) spanning ≥3 vertebral segments, with conus medullaris involvement common 1
• Brainstem encephalitis: Can involve area postrema causing intractable nausea/vomiting or hiccups 1
• ADEM-like presentations: Particularly common in children, with large confluent T2 brain lesions and encephalopathy 1, 2
• Cortical encephalitis: With acute respiratory insufficiency, altered consciousness, behavioral changes, or seizures 1

Disease Course

• Relapsing pattern: Approximately 40-80% of patients experience relapses, though the course is variable 3, 2
• Age distribution: Occurs across all ages but peaks around the fourth decade; significantly more common in children (up to 70% of pediatric acquired demyelinating disease) than adults (≤1% in Western countries) 1, 4
• Gender: Unlike AQP4-NMOSD, MOGAD shows no marked female predominance 4

Diagnostic Approach

When to Test for MOG-IgG

Critical caveat: Indiscriminate screening reduces positive predictive value and leads to false positives and inappropriate treatment. Testing should be reserved for specific clinical scenarios 1.

Test MOG-IgG when patients present with acute CNS demyelination AND radiological/electrophysiological findings compatible with demyelination AND at least one of these features 1:

High-Yield MRI Features:

• Longitudinally extensive spinal cord lesion (≥3 vertebral segments) or atrophy
• Conus medullaris lesions at onset
• Longitudinally extensive optic nerve lesion with perioptic gadolinium enhancement
• Normal supratentorial MRI despite ON, myelitis, or brainstem symptoms
• Brain lesions that do NOT meet MS criteria (no periventricular ovoid lesions, no Dawson's fingers, no juxtacortical U-fiber lesions)
• Large confluent T2 brain lesions suggesting ADEM

High-Yield Clinical Features:

• Simultaneous bilateral acute ON
• Recurrent ON or disease predominantly characterized by ON
• Severe visual deficit/blindness during or after acute ON
• Severe or frequent myelitis/brainstem encephalitis episodes
• Permanent sphincter/erectile dysfunction after myelitis
• ADEM, recurrent ADEM, or multiphasic ADEM presentations
• Disease onset 4 days to ~4 weeks post-vaccination

High-Yield CSF Features:

• Neutrophilic pleocytosis or WCC >50/μL
• Absence of CSF-restricted oligoclonal bands (particularly relevant in continental European patients)

Treatment Response Red Flags:

• Frequent flare-ups after IV methylprednisolone or steroid-dependent symptoms
• Increased relapse rate following interferon-beta or natalizumab treatment in patients diagnosed with MS

Testing Methodology

Use cell-based assays with full-length human MOG protein only - older ELISA methods using denatured MOG peptides are unreliable and should not be used 1. Live cell-based assays are preferred over fixed cell assays, and antibody titers matter (low titers increase false-positive risk) 2.

Distinction from MS and AQP4-NMOSD

Key Differentiating Features:

MOGAD vs. MS:

• MOGAD shows T2-lesion resolution over time (radiologic lag phenomenon), while MS lesions persist 5
• MOGAD lacks periventricular ovoid lesions and Dawson's fingers typical of MS 1
• MOGAD rarely shows asymptomatic radiological activity between attacks 5
• 33% of MOGAD patients may meet McDonald MS criteria at some point, creating diagnostic confusion 1

MOGAD vs. AQP4-NMOSD:

• Both can present with LETM and ON, but MOGAD generally has better functional prognosis 2, 4
• MOGAD more commonly involves conus medullaris and shows prominent optic disc swelling 1
• MOGAD typically lacks the severe, permanent disability seen in AQP4-NMOSD attacks 4

Clinical Implications

The distinction matters critically for treatment: Some MS disease-modifying therapies (interferon-beta, natalizumab) may be ineffective or harmful in MOGAD, similar to what has been observed in AQP4-NMOSD 1. Misdiagnosis as MS can lead to inappropriate treatment escalation and potentially worse outcomes.

Prognosis: MOGAD generally responds well to acute immunotherapy (IV steroids, plasma exchange) and has better functional recovery than AQP4-NMOSD, though relapses are common and may require long-term immunosuppression 3, 2, 4.